SK Bioscience

Summary

History

Mission

Vision

References

Summary

SK bioscience Co.,Ltd. engages in the research and development, production, and distribution of vaccines and biopharmaceuticals in Korea and internationally. Its product portfolio includes Skycellflu, a cell cultured influenza surface antigen vaccine; Skycellflu 4-ga pre-filled syringe; pneumococcal vaccine for adult and infant; Skyzoster, a shingles virus vaccine; and Sky Baricella for the prevention of chickenpox infection in children. The company also engages in the development of oral rotavirus vaccine that has completed phase 2 clinical trial; cervical cancer vaccine, which has completed phase 2 clinical trial; rotavirus vaccine that is in phase 3 clinical trial in Africa; typhoid conjugate vaccine; and Corona 19 vaccine that is in phase 1 and phase 1/2 clinical trials; and low-cost pneumococcal vaccine, which has completed phase 2 clinical trial and next-generation pneumococcal vaccine that is in phase 2 clinical trial in the United States. SK bioscience Co.,Ltd. was founded in 2018 and is based in Seongnam-si, South Korea.

History

SK Biotekhno Co. was established in 1991 as the first biopharmaceutical company in South Korea. It was founded as part of a national effort to promote the biotechnology industry and to provide high-quality biopharmaceutical products to the public. Since then, it has become the world's leading innovator of biotech drugs and a leader in the sector

Mission

SK Biotekhno’s mission is to develop research on life sciences, create innovative biopharmaceuticals, and create a better life for all

Vision

SK Biotekhno’s vision is to be the best biopharmaceutical company in the world, creating innovative therapies and improving healthcare outcomes.

References

https://in.investing.com/equities/sk-bioscience-co

https://finance.yahoo.com/quote/302440.KS/profile?p=302440.KS

https://www.crunchbase.com/organization/sk-bioscience

https://www.skbioscience.co.kr

Leadership team

Mr. Jae-Yong Ahn (CEO, Pres & Director)

Ms. SookMi Hwang (Head of Global Regulatory Affairs)